Lukas Scheibler - Chief Research Officer at Apellis Pharmaceuticals, Inc.

Insider Transactions and Holdings

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Common Stock	68.3K	$4.35M	$63.69	Dec 1, 2023	Direct
Stock Option (Right to Buy)	39.4K	$2.61M	$66.30	Dec 1, 2023	Direct	Common Stock

Showing 1 to 2 of 2 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.